Supernus Pharmaceuticals (SUPN) Cash & Equivalents Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Cash & Equivalents Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | -4.65% |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 24.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.35% |
| Mar 31, 2026 | 59.58% |
| Dec 31, 2025 | 85.27% |
| Sep 30, 2025 | 377.92% |
| Jun 30, 2025 | 177.81% |
| Mar 31, 2025 | 82.72% |
| Dec 31, 2024 | -7.63% |
| Sep 30, 2024 | -66.65% |
| Jun 30, 2024 | 110.84% |
| Mar 31, 2024 | 8.49% |
| Dec 31, 2023 | -19.40% |
| Sep 30, 2023 | -14.81% |
| Jun 30, 2023 | -85.75% |
| Mar 31, 2023 | -49.49% |
| Dec 31, 2022 | -54.23% |
| Sep 30, 2022 | -48.21% |
| Jun 30, 2022 | -22.50% |
| Mar 31, 2022 | -54.74% |
| Dec 31, 2021 | -29.52% |
| Sep 30, 2021 | 5.38% |